Get the Stockscreener App
171.56
1.23%
-2.14
After Hours:
171.60
0.04
+0.02%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $171.56, with a volume of 6.73M.
It is down -1.23% in the last 24 hours and down -2.18% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$173.70
Open:
$172.88
24h Volume:
6.73M
Relative Volume:
1.19
Market Cap:
$303.17B
Revenue:
$55.53B
Net Income/Loss:
$5.12B
P/E Ratio:
59.57
EPS:
2.88
Net Cash Flow:
$15.62B
1W Performance:
-2.06%
1M Performance:
-2.18%
6M Performance:
-2.12%
1Y Performance:
+5.88%
1-Day Range:
$171.27
$173.99
1-Week Range:
$168.72
$177.98
52-Week Range:
$153.58
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.
AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey
Diversify Advisory Services LLC Sells 6,472 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Artemis Investment Management LLP Has $85.98 Million Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Brady Martz Wealth Solutions LLC Takes Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Ameritas Advisory Services LLC - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Wealth Alliance Advisory Group LLC - MarketBeat
Jackson Square Capital LLC Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Cohen Klingenstein LLC Reduces Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Avanza Fonder AB Acquires Shares of 8,443 AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Short Interest Update - MarketBeat
Why Is AbbVie Inc. (ABBV) Among Louis Navellier’s Top Long-term Stock Picks? - Insider Monkey
AbbVie Inc. (NYSE:ABBV) Position Raised by Lake Street Private Wealth LLC - MarketBeat
AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth - MSN
Brooklyn Investment Group Has $2.73 Million Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Householder Group Estate & Retirement Specialist LLC Reduces Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Wedge Capital Management L L P NC Trims Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Channel Wealth LLC Has $1.68 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Yarger Wealth Strategies LLC - MarketBeat
AbbVie Inc. (NYSE:ABBV) Stock Holdings Lifted by KMG Fiduciary Partners LLC - MarketBeat
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt - Benzinga
Two more AbbVie drugs put on the Medicare negotiation list - Crain's Chicago Business
AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs - MSN
Decker Retirement Planning Inc. Purchases New Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie stock target cut, keeps Buy rating on growth outlook - Investing.com
FY2024 Earnings Forecast for AbbVie Issued By Zacks Research - MarketBeat
Tallon Kerry Patrick Buys New Shares in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mason & Associates Inc Acquires 1,499 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Giant-Cell Arteritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA, and Developments | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys - Barchart
Why the Market Dipped But AbbVie (ABBV) Gained Today - Yahoo Finance
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
BMO maintains AbbVie stock Outperform rating - MSN
AbbVie's Quarterly Earnings Preview: What You Need to Know - Nasdaq
Humira Holds Firm at 72% Market Share-AbbVie Fends Off Biosimila - GuruFocus.com
AbbVie and Simcere Join Forces for Multiple Myeloma Breakthrough - Zenopa
Humira Holds Firm at 72% Market Share-AbbVie Fends Off Biosimilar Surge - Yahoo Finance
AbbVie retains Humira market share above 70%: report - MSN
AbbVie retains Humira market share amid biosimilars (ABBV:NYSE) - Seeking Alpha
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
JPM Day 3: AbbVie, Gilead, GSK and Dyne - PharmaLive
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson - BioPharma Dive
Future Industry Growth Of Antiviral Drugs Market by 2024 To 2031 | AbbVie Inc., GSK plc, Dr. Reddy's - EIN News
AbbVie Inc. (NYSE:ABBV) Shares Purchased by BluePath Capital Management LLC - MarketBeat
Sawyer & Company Inc Sells 3,161 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Psoriasis Drugs Market Growth Drivers, Revenue, and Size - openPR
Wolff Wiese Magana LLC Acquires 1,750 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Meyer Handelman Co. Has $27.52 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Radnor Capital Management LLC Has $4.38 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's Quarterly Earnings Preview: What You Need To Know - Barchart
The Zacks Analyst Blog Highlights Visa, AbbVie, Analog Devices and Precipio - Yahoo Finance
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole - Yahoo Finance
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):